Dr. Reddy's Laboratories launches Bortezomib for Injection, 3.5 mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (bortezomib) Injection, in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).

The Velcade® Brand and generic had U.S. sales of approximately $1.2 billion MAT for the most recent twelve months ending in May 2022 according to IQVIA Health*.

Dr. Reddy's Bortezomib for Injection, is supplied in a 3.5 mg per 10 mL single-dose vial presentation for subcutaneous (SQ) or intravenous (IV) use.

Shares of Dr. Reddy's Laboratories Limited was last trading in BSE at Rs. 4211.50 as compared to the previous close of Rs. 4332.15. The total number of shares traded during the day was 11840 in over 2625 trades.

The stock hit an intraday high of Rs. 4326.05 and intraday low of 4195.00. The net turnover during the day was Rs. 49969289.00.

Source : Equity Bulls

Keywords

DrReddysLaboratories INE089A01023 RDY BortezomibInjection Velcade USFDA